EXHIBIT 99.1
 (I-FLOW LOGO)I-FLOW 
CORPORATION
    
    20202 Windrow DriveLake Forest, CA 92630
(800) 448-3569 (949) 206-2700
Fax (949) 206-2600
    

FOR IMMEDIATE RELEASEInvestor Contact:
    
    
    
    
    
    Company Contact:Neil Berkman
Berkman Associates
(310) 826-5051info@BerkmanAssociates.com
    
    
    
    
    
    James R. Talevich
Chief Financial Officer
(949) 206-2700www.iflo.com
 I-Flow Announces Two Million Share Increase
in Common Stock Repurchase Plan
 LAKE FOREST, Calif. I-Flow Corporation (NASDAQ: IFLO)
  About I-Flow
 www.IFLO.com
 Safe Harbor Statement
 Statements by the Company in this press release and in other reports and statements
released by the Company are and will be forward-looking in nature and express the Companys
current opinions about trends and factors that may impact future operating results.
Statements that use words such as may, will, should, believes, predicts,
estimates, projects, anticipates, or expects or use similar expressions are intended
to identify forward-looking statements. Forward-looking statements are subject to material
risks, assumptions and uncertainties, which could cause actual results to differ materially
from those currently expected, and readers are cautioned not to place undue reliance on these
forward-looking statements. Except as required by law, the Company undertakes no obligation
to publish revised forward-looking statements to reflect the occurrence of unanticipated or
subsequent events. Readers are also urged to carefully review and consider the various
disclosures made by the Company in this press release that seek to advise interested parties
of the risks and other factors that affect the Companys business. Interested parties should
also review the Companys reports on Forms 10-K, 10-Q and 8-K and other reports that are periodically filed with the Securities and
Exchange Commission. The risks affecting the Companys business include, among others:
physician acceptance of infusion-based therapeutic regimens; implementation of the Companys
direct sales strategy; successful integration of the Companys recent acquisition of AcryMed
Incorporated and further development and commercialization of AcryMeds technologies;
potential inadequacy of insurance to cover existing and future product liability claims;
dependence on the Companys suppliers and distributors; the Companys continuing compliance
with applicable laws and regulations, such as the Medicare Supplier Standards and Food, Drug
and Cosmetic Act, and Medicares and the FDAs concurrence with managements subjective
judgment on compliance issues, including those related to the recent FDA warning letter; the
reimbursement system currently in place and future changes to that system; product
availability, acceptance and safety; competition in the industry; technological changes;
intellectual property challenges and claims; economic and political conditions in foreign
countries; currency exchange rates; inadequacy of booked reserves or
future impairment expenses; and reliance on the success of the home health care industry. All
forward-looking statements, whether made in this press release or elsewhere, should be
considered in context with the various disclosures made by the Company about its business.